The Developmental Research Program of the University of Pittsburgh Head and Neck Cancer SPORE will continue to be carried out for the purpose of identifying and facilitating innovative new pilot projects in head and neck cancer research. The specific goals of this Program are: 1) to provide seed funding opportunities for initial investigation of promising novel research in head and neck cancer;2) to stimulate basic, clinical, and translational head and neck cancer research in areas of high priority to the Head and Neck Cancer SPORE;3) to facilitate development of pilot projects into full project status in the Head and Neck Cancer SPORE or to be competitive for independent Investigator-initiated proposals to other funding agencies;and 4) to increase the visibility of Head and Neck Cancer SPORE activities and increase participation among the institution's clinicians and researchers. Our design for the Developmental Research Program in this renewal application is similar to the process used during the first grant period, which proved successful. Drs. William L. Bigbee, Susanne M. Gollin and Jonas T. Johnson, with ongoing experience in administering this Developmental Program, will continue to provide leadership for translational research. The Developmental Research Program will utilize institutional web-based resources and printed announcements to notify the research community at the University of Pittsburgh and Carnegie Mellon University of the availability of research funds to support pilot projects in head and neck cancer. In response to the new SPORE guidelines encouraging inter-institutional collaboration, we will also make the program available to our sister Cancer Centers in Philadelphia, who are part of the stateside Pennsylvania Cancer Control Consortium (PAC-3) initiative. A standing Developmental Research Program Committee, together with ad hoc reviewers with specific expertise as needed drawn from the UPCI, UPMC, the Head and Neck Cancer SPORE External Advisory Board, or other Head and Neck SPOREs will provide rigorous and consistent peer review of the solicited project proposals. The proposed Developmental Research Program budget will include $100,000 per year in funds form the NCI through this proposal, together with an additional $100,000 per year in matching funds from the Department of Otolaryngology (through the Eye and Ear Foundation of Pittsburgh) and the UPCI. Proposals will be solicited and reviewed on an annual basis and grants of $30,000-$50,000 per year for 1-2 years will be awarded to the most meritorious proposals. These activities of the Developmental Research Program will continue to stimulate innovative research toward meeting the translational goals of the Head and Neck Cancer SPORE: reduction in the incidence, morbidity, and mortality from head and neck cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Albergotti, William G; Gooding, William E; Kubik, Mark W et al. (2017) Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx. JAMA Otolaryngol Head Neck Surg 143:542-548
Jie, Hyun-Bae; Srivastava, Raghvendra M; Argiris, Athanassios et al. (2017) Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. Cancer Immunol Res 5:408-416
Kubik, Mark; Mandal, Rajarsi; Albergotti, William et al. (2017) Effect of transcervical arterial ligation on the severity of postoperative hemorrhage after transoral robotic surgery. Head Neck 39:1510-1515
Patel, Snehal G; Carty, Sally E; McCoy, Kelly L et al. (2017) Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery 161:168-175
Srivastava, Raghvendra M; Trivedi, Sumita; Concha-Benavente, Fernando et al. (2017) CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clin Cancer Res 23:707-716
Concha-Benavente, Fernando; Ferris, Robert L (2017) Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 45:52-59
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Andrews, Lawrence P; Marciscano, Ariel E; Drake, Charles G et al. (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80-96
Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2017) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res :
Godse, Neal R; Khan, Nayel; Yochum, Zachary A et al. (2017) TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clin Cancer Res 23:7324-7332

Showing the most recent 10 out of 289 publications